

A PET Radiopharmaceutical for Early Prediction of ADPKD Progression

Published date: Jan. 13, 2015

Technology description

This invention describes specific radiopharmaceuticals and a method for using positron emission tomography (PET) to accurately predict autosomal dominant polycystic kidney disease (ADPKD) progression in the early stages of disease. ADPKD is the fourth leading cause of kidney failure in the U.S. In spite of significant structural damage, renal function in ADPKD patients is maintained within a normal range until the late stage of the disease. Thus, the effectiveness of a therapeutic intervention is low in ADPKD patients with established renal insufficiency since significant structural damage has already occurred. However, no diagnostic tool is currently available to identify patients who are at higher risk of rapidly progressing ADPKD and would be more likely to benefit from a therapeutic intervention. The invention disclosed here will fulfill this clinical need.

Institution

[University of Oklahoma](#)

Inventors

[Benjamin Cowley, Jr.](#)

Faculty

Medicine, Nephrology

[Hariprasad Gali](#)

Faculty

Pharmaceutical Sciences

联系我们



叶先生

电话 : 021-65679356

手机 : 13414935137

邮箱 : yeyingsheng@zf-ym.com